en
Scientific article
Open access
English

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Published inNature communications, vol. 15, no. 1, 2054
Publication date2024-03-06
First online date2024-03-06
Abstract

Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells. The Fc portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent cell cytotoxicity and antibody dependent cell phagocytosis. ISB 1442 thus represents a CD47-BsAb combining biparatopic targeting of a tumor associated antigen with engineered enhancement of antibody effector function to overcome potential resistance mechanisms that hamper treatment of myeloma with monospecific anti-CD38 antibodies. ISB 1442 is currently in a Phase I clinical trial in relapsed refractory multiple myeloma.

eng
Keywords
  • Humans
  • Multiple Myeloma / drug therapy
  • CD47 Antigen
  • Antibodies, Bispecific / pharmacology
  • Antibodies, Bispecific / therapeutic use
  • Hematologic Neoplasms
  • Antibody-Dependent Cell Cytotoxicity
Citation (ISO format)
GRANDCLÉMENT, C et al. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. In: Nature communications, 2024, vol. 15, n° 1, p. 2054. doi: 10.1038/s41467-024-46310-y
Main files (1)
Article (Published version)
Secondary files (9)
Identifiers
ISSN of the journal2041-1723
13views
1downloads

Technical informations

Creation05/30/2024 1:18:09 PM
First validation05/30/2024 3:08:06 PM
Update time05/30/2024 3:08:06 PM
Status update05/30/2024 3:08:06 PM
Last indexation05/30/2024 3:08:26 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack